Prohost Biotech - Exclusive Biotech Research - A Comprehensive Resource for Biotech News

BioStem Technologies’ Press Release and Conference Call Offered Encouraging News

April 2, 2024 0

BioStem Technologies Inc From Jason Matuszewski, CEO of BioStem Technologies (BSEM), who stated, “BioStem had an …

BioStem Technologies is Releasing its Fourth Quarter 2023 Financial Results Now

April 1, 2024 0

BioStem Technologies to Release Fourth Quarter Results BioStem Technologies (BSEM) is hosting a conference call and …

Verrica Pharmaceuticals Announced the FDA Granted YCANTHTM New Chemical Entity Status and Orange Book Listing

March 28, 2024 0

We are currently working to bring into the upcoming ProhostBiotech Letter some small clinical and commercial …

AbbVie Inc’s Two Different, Yet, Positive Impacting News

March 26, 2024 0

AbbiVie Inc's Acquisition and Approval 1. AbbVie's Acquisition AbbVie Inc. (ABBV) and Landos Biopharma, Inc. …

Novo Nordisk Aims to Acquire Cardior Pharmaceuticals, Strengthening Its Pipeline in Cardiovascular Disease

March 25, 2024 0

Novo Nordisk in the NEWS Novo Nordisk (NVO) and Cardior Pharmaceuticals announced that Novo Nordisk agreed …

Italfarmaco Received FDA Approval for Duvyzat™ for the Treatment of Duchenne Muscular Dystrophy

March 22, 2024 0

Italfarmaco in the NEWS From Milan, Italy: Today, Italfarmaco announced that the U.S. Food and Drug …

Illumina Stock Price Will Rebound With or Without This News

March 22, 2024 0

Illumina in the NEWS On March 21, 2024, we learned that the EU antitrust regulators suffered …

Selecting New Small Biotech Firms for Investment

March 20, 2024 0

During a discussion with colleagues about the best way to select small and new biotechnology firms …

Madrigal Pharmaceuticals Announces FDA Approval of Rezdiffra for the Patients with NASH That Have Moderate to Advanced Liver Fibrosis

March 15, 2024 0

Madrigal Pharmaceuticals in the NEWS Yesterday, March 14, 2024 Madrigal Pharmaceuticals (MDGL) announced that the U.S. …

Today’s Bad, Bear Market and Cullinan Oncology Providing 2023 Accomplishments and Financial Results

March 14, 2024 0

The Market Today the Stock Market is bearish and most of the biotech stocks are down …

Arcturus Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results, Provides Corporate Update and Hosts a Conference Call

March 7, 2024 0

Arcturus Therapeutics Fourth Quarter and Full Year 2023 Earnings Conference Call Before listening to the Conference …

Compugen Reports Fourth Quarter and Full Year 2023 Results

March 6, 2024 0

Compugen in the NEWS Compugen (CGEN) offered its fourth Quarter and full year 2023 results yesterday, …

BioCardia Inc Reports Positive Interim Results from Phase III CardiAMP Cell Therapy Heart Failure Trial

March 4, 2024 0

BioCardia Inc in the NEWS BioCardia, Inc. (BCDA), a biotechnology company focused on advancing late-stage cell therapy …

Akero Therapeutics Reports Statistically Significant Histological Improvements at Week 96 in Phase 2b HARMONY Study

March 4, 2024 0

Akero Therapeutics Akero Therapeutics (AKRO) released preliminary topline week 96 results from HARMONY, a Phase 2b …

Prohost Letter #459 ~ NAFLD & NASH

March 3, 2024 0

Prohost Letter #459 ~ NAFLD & NASH NAFLD is Non-Alcoholic Fatty Liver Disease, and NASH is …

Verrica Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Results

February 29, 2024 0

Verrica Pharmaceuticals Verrica Pharmaceuticals (VRCA) is a dermatology therapeutics company developing medications for skin diseases. …

Krystal Biotech Announced Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates

February 26, 2024 0

Krystal Biotech Today, February 26, 2024, Krystal Biotech (KRYS) firm announces its full year financial results …

Vertex Receives CHMP Positive Opinion for KALYDECO® for the Treatment of Infants with Cystic Fibrosis Ages 1 Month and Older

February 23, 2024 0

Vertex Pharmaceuticals in the NEWS Vertex Pharmaceuticals (VRTX) announced that the European Medicines Agency’s (EMA’s) Committee …

CRISPR Therapeutics Financial Results for Fourth Quarter and Full Year Ended December 31, 2023 Plus All You Need To Know About this Firm’s Capabilities

February 22, 2024 0

CRISPR Therapeutics Since its inception over a decade ago, CRISPR Therapeutics (CRSP) has transformed from a …

Ionis Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results

February 21, 2024 0

Ionis Pharmaceuticals For three decades, Ionis Pharmaceuticals (IONS) invented medicines to treat serious diseases. Currently, Ionis …

Exclusive Market Insight

& Scientific analysis

Latest Articlesddd

BioStem Technologies’ Press Release and Conference Call Offered Encouraging News

BioStem Technologies is Releasing its Fourth Quarter 2023 Financial Results Now

Verrica Pharmaceuticals Announced the FDA Granted YCANTHTM New Chemical Entity Status and Orange Book Listing

AbbVie Inc’s Two Different, Yet, Positive Impacting News

Novo Nordisk Aims to Acquire Cardior Pharmaceuticals, Strengthening Its Pipeline in Cardiovascular Disease

Italfarmaco Received FDA Approval for Duvyzat™ for the Treatment of Duchenne Muscular Dystrophy

Illumina Stock Price Will Rebound With or Without This News

Selecting New Small Biotech Firms for Investment

Madrigal Pharmaceuticals Announces FDA Approval of Rezdiffra for the Patients with NASH That Have Moderate to Advanced Liver Fibrosis

Today’s Bad, Bear Market and Cullinan Oncology Providing 2023 Accomplishments and Financial Results

Arcturus Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results, Provides Corporate Update and Hosts a Conference Call

Compugen Reports Fourth Quarter and Full Year 2023 Results

BioCardia Inc Reports Positive Interim Results from Phase III CardiAMP Cell Therapy Heart Failure Trial

Akero Therapeutics Reports Statistically Significant Histological Improvements at Week 96 in Phase 2b HARMONY Study

Prohost Letter #459 ~ NAFLD & NASH

Verrica Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Results

Krystal Biotech Announced Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates

Vertex Receives CHMP Positive Opinion for KALYDECO® for the Treatment of Infants with Cystic Fibrosis Ages 1 Month and Older

CRISPR Therapeutics Financial Results for Fourth Quarter and Full Year Ended December 31, 2023 Plus All You Need To Know About this Firm’s Capabilities

Ionis Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results